These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 7673726

  • 1. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.
    Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C.
    J Immunol; 1995 Sep 15; 155(6):3112-23. PubMed ID: 7673726
    [Abstract] [Full Text] [Related]

  • 2. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
    Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, Cavallo F, Di Pierro F, Novelli F, Forni G.
    J Immunol; 1994 Dec 15; 153(12):5659-73. PubMed ID: 7989764
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
    Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G.
    J Immunol; 1992 Dec 01; 149(11):3627-35. PubMed ID: 1358974
    [Abstract] [Full Text] [Related]

  • 5. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
    Di Carlo E, Coletti A, Modesti A, Giovarelli M, Forni G, Musiani P.
    Eur Cytokine Netw; 1998 Mar 01; 9(1):61-8. PubMed ID: 9613679
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M, Argentati K, Tibaldi A.
    Gene Ther; 2000 Apr 01; 7(7):624-32. PubMed ID: 10819579
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.
    Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G.
    J Immunol; 1995 May 15; 154(10):5302-12. PubMed ID: 7730633
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
    Musiani P, Modesti A, Brunetti M, Modica A, Vitullo P, Gulino A, Bosco MC, Colombo MP, Nanni P, Cavallo F.
    Nat Immun; 1994 May 15; 13(2-3):93-101. PubMed ID: 8173240
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.
    Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW, Chang AE.
    Cancer Gene Ther; 1997 Aug 01; 4(3):157-66. PubMed ID: 9171934
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Kuzushita N, Ito A, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Hepatology; 1999 Aug 01; 30(2):422-9. PubMed ID: 10421650
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.